Search

Ferumoxytol

[L54501] The drug remains approved in the US, with a new indication being approved in October of 2025 for Ferumoxytol's use as a diagnostic agent for MRI of the brain. … In January of 2015, the EMA withdrew marketing authorisation for Rienso (ferumoxytol) due to safety concerns.

Isoniazid

Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.

Borneol

Estetrol

The combination of drospirenone and estetrol offers a new choice with a favourable safety profile for women seeking contraceptive therapy. … [L33184] Estetrol (E4) is a native estrogen occurring naturally during pregnancy, but can be synthesized from a plant source and used for contraception.

Erdafitinib

[L5956, L5959] At the same time, the FDA also approved the therascreen FGFR RGQ RT-PCR Kit (Qiagen) for utilization as a companion diagnostic with erdafitinib for selecting patients for the indicated therapy … tool kit to treat such a prevalent medical condition.

Selexipag

PAH is a relatively rare disease with usually a poor prognosis requiring more treatment options to prolong long-term outcomes. … Selexipag was approved by the United States FDA on December 22, 2015 for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression and reduce risk of hospitalization.

Streptococcus pneumoniae type 5 capsular polysaccharide antigen

It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia. … Streptococcus pneumoniae type 5 capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 5 of *Streptococcus pneumoniae*.

Streptococcus pneumoniae type 23f capsular polysaccharide antigen

It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia. … Streptococcus pneumoniae type 23f capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 23f of *Streptococcus pneumoniae

Sofosbuvir

With the price per pill set at $1000, a 12-week treatment can cost upwards of $84,000 per patient [A19636]. … the intent to cure, or achieve a sustained virologic response (SVR), after 12 weeks of daily therapy.